What does the term ascus mean?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ASCUS: Atypical Squamous Cells of Undetermined Significance

ASCUS stands for "Atypical Squamous Cells of Undetermined Significance" - a cervical cytology diagnosis introduced by The Bethesda System in 1988 to describe borderline cellular changes on Pap smears that are more abnormal than normal but lack sufficient criteria to definitively diagnose a squamous intraepithelial lesion (SIL). 1

What This Diagnosis Means

ASCUS represents a gray zone in cervical cytology where cells show abnormalities suggestive of a precancerous lesion but don't meet the threshold for a definitive diagnosis. This category affects approximately 2-3 million women annually in the United States 2. The clinical significance is variable - roughly 10% of ASCUS patients will develop SIL, and approximately 1 in 1,000 will develop cervical cancer 3.

Clinical Subclassifications

ASCUS should be further categorized into five subgroups for appropriate management 1, 4:

  1. ASCUS due to processing defects - technical issues with specimen preparation
  2. ASCUS with "mature" intermediate-type cytoplasm - most common subtype
  3. ASCUS in postmenopausal women (subdivided into: a) atrophy-related, b) with estrogen stimulation)
  4. Atypical metaplasia
  5. ASCUS with keratinized/orangeophilic cytoplasm

Management Algorithm by Subtype

For ASCUS types with mature cytoplasm or keratinized cytoplasm (types 2 and 5):

  • Three management options exist: cytologic follow-up with colposcopy only if ASCUS persists, immediate colposcopy, or combined HPV testing with repeat Pap test 4

For ASCUS due to processing defects (type 1):

  • Immediately repeat Pap test if processing defects are the cause
  • If excessive inflammation is present, repeat after treating the inflammation 4

For postmenopausal ASCUS (type 3):

  • If receiving hormone replacement therapy: follow standard options above
  • If NOT receiving hormone replacement: repeat Pap test after topical estrogen therapy 4

For atypical metaplasia (type 4):

  • More aggressive follow-up required: proceed directly to colposcopy with potential biopsy 4

Natural History and Regression

Studies show a 73% regression rate for ASCUS on follow-up 5. After six months of follow-up, the majority of cases (approximately 73%) return to normal cytology, while a minority persist with ASCUS findings 5.

Risk Stratification

High-risk HPV testing is critical for risk stratification. Among ASCUS cases, 27.2% carry high-risk HPV genomes compared to only 1.5% of normal controls 3. The combination of high-risk HPV positivity with DNA aneuploidy (cells with DNA content above 9c) identifies patients at highest risk for progression to high-grade lesions - these cases behave similarly to high-grade SIL and warrant aggressive management 3.

Key Clinical Pitfall

The major challenge with ASCUS is its lack of reproducibility between pathologists and the risk of both overdiagnosis (leading to unnecessary procedures) and underdiagnosis (missing significant lesions) 2. Effective communication between cytopathologist and clinician is essential - pertinent patient information including age, menstrual status, mechanical therapies, and medication history (especially tamoxifen) must be provided to avoid inappropriate management 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.